CONMED Corporation CNMD raised its 2026 adjusted earnings outlook after a better-than-expected second quarter, testing whether stronger execution can translate into more durable earnings momentum.
The revision comes with a more measured organic growth outlook and higher expected financing costs. That mix keeps the focus on margins, core-platform execution and cash generation through the second half.
CONMED Lifts Its 2026 Earnings Expectations
CONMED now expects 2026 adjusted earnings of $4.48-$4.60 per share, up from $4.30-$4.45. The increase reflects better-than-expected second-quarter results, a lower projected earnings headwind from the gastroenterology product exits and a higher contribution from share repurchases.
Higher interest expense and an increased tax-rate assumption partly offset those benefits. The revised range therefore depends on operating gains holding up despite a less favorable financing backdrop.
CNMD’s Second Quarter Provides the Foundation
Second-quarter adjusted earnings rose 20% year over year to $1.38 per share and beat the Zacks Consensus Estimate by 25.5%. Revenues reached $343.5 million, up 0.3%, and exceeded the consensus mark by 1.9%. Organic constant-currency revenues excluding gastroenterology increased 6%.
Stryker Corporation SYK is a relevant medtech peer because its portfolio spans MedSurg, Neurotechnology and Orthopaedics. Medtronic plc MDT also provides useful industry context through technologies that include surgical robotics and surgical tools.
CONMED’s Margin Expansion Adds Earnings Leverage
Adjusted gross margin reached 59.5% in the second quarter, up 300 basis points year over year. An $8.5 million tariff refund accounted for about 250 basis points of the increase.
Excluding that benefit, adjusted gross margin still improved 50 basis points, helped by favorable product mix and foreign currency. Reported gross margin rose 250 basis points to 57.5%, reinforcing that the quarter’s margin improvement was not solely refund-driven.
CNMD’s Second-Half Growth Path Remains Measured
Management now expects 2026 organic constant-currency revenue growth of 5%-6%, compared with its prior 5%-6.5% outlook. The lower top end reflects a more measured pace of sequential growth improvement in the second half.
For the third quarter, CONMED expects organic constant-currency growth of 6.4%-7.6%, excluding anticipated gastroenterology revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted earnings are projected at 98 cents to $1.03 per share.
CONMED’s Financial Headwinds Limit the Upside
The financing picture remains a constraint. Expected 2026 adjusted interest expense increased to about $33 million from the prior $25-$27 million range following the company’s debt refinancing.
Free cash flow guidance also fell to about $115 million from roughly $125 million, partly reflecting inventory and working-capital needs. Sustained execution across AirSeal, Buffalo Filter and BioBrace will matter more if CONMED is to convert higher earnings expectations into stronger cash generation.
CNMD’s Signals Reflect Improving but Mixed Momentum
The raised earnings outlook improves the near-term fundamental picture, but the narrower organic growth range and higher financing costs keep the setup mixed. The stock’s prospects still depend on consistent execution across core platforms, margins and working capital.
CNMD currently carries a Zacks Rank #3 (Hold), along with a VGM Score of B, Value Score of A, Growth Score of C and Momentum Score of C. The Value Score signals relative strength on valuation measures, while the C grades for Growth and Momentum are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. With a Zacks Rank #3, the combined signals support a measured stance rather than a clear near-term buy signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CONMED Corporation (CNMD): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
